↓ Skip to main content

Dove Medical Press

Article Metrics

Tipepidine in children with attention deficit/hyperactivity disorder: a 4-week, open-label, preliminary study

Overview of attention for article published in Neuropsychiatric Disease and Treatment, January 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (80th percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

twitter
6 tweeters
wikipedia
1 Wikipedia page

Readers on

mendeley
11 Mendeley
Title
Tipepidine in children with attention deficit/hyperactivity disorder: a 4-week, open-label, preliminary study
Published in
Neuropsychiatric Disease and Treatment, January 2014
DOI 10.2147/ndt.s58480
Pubmed ID
Authors

Tsuyoshi Sasaki, Kenji Hashimoto, Masumi Tachibana, Tsutomu Kurata, Keiko Okawada, Maki Ishikawa, Hiroshi Kimura, Hideki Komatsu, Masatomo Ishikawa, Tadashi Hasegawa, Akihiro Shiina, Tasuku Hashimoto, Nobuhisa Kanahara, Tetsuya Shiraishi, Masaomi Iyo

Abstract

Tipepidine (3-[di-2-thienylmethylene]-1-methylpiperidine) has been used solely as a nonnarcotic antitussive in Japan since 1959. The safety of tipepidine in children and adults has already been established. It is reported that tipepidine inhibits G-protein-coupled inwardly rectifying potassium (GIRK)-channel currents. The inhibition of GIRK channels by tipepidine is expected to modulate the level of monoamines in the brain. We put forward the hypothesis that tipepidine can improve attention deficit/hyperactivity disorder (ADHD) symptoms by modulating monoaminergic neurotransmission through the inhibition of GIRK channels. The purpose of this open-label trial was to confirm whether treatment with tipepidine can improve symptoms in pediatric patients with ADHD.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 2 18%
Unknown 9 82%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 27%
Student > Bachelor 2 18%
Student > Doctoral Student 2 18%
Unspecified 1 9%
Other 1 9%
Other 2 18%
Readers by discipline Count As %
Medicine and Dentistry 6 55%
Psychology 2 18%
Unspecified 1 9%
Chemistry 1 9%
Neuroscience 1 9%
Other 0 0%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 August 2015.
All research outputs
#950,874
of 5,436,873 outputs
Outputs from Neuropsychiatric Disease and Treatment
#179
of 1,163 outputs
Outputs of similar age
#28,127
of 144,421 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#10
of 97 outputs
Altmetric has tracked 5,436,873 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,163 research outputs from this source. They receive a mean Attention Score of 4.7. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 144,421 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 97 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.